Chronic systemic treatment with a proteasome inhibitor has been linked to a Parkinsonian phenotype, characterized by dopaminergic neuron loss and the formation of alpha-synuclein-effective inclusions, emphasizing the complex interplay between ubiquitination and the pathogenesis of Parkinsons disease (Davies et al. 2014). The gene discussed is SNCA; the disease is Parkinson disease.